Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taletrectinib in ROS1-positive NSCLC and other solid tumors
NCT04919811Phase 2Active, not recruiting
- Sponsor
- Nuvation Bio
- Start
- Sep 2021
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of taletrectinib in non-small cell lung cancer (NSCLC), sponsored by Nuvation Bio. Primary endpoint: Objective Response Rate by Independent Radiology Review Committee at 4 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04919811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919811.